Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$10.3MCash on Hand
12.1mo Cash Runway
Follow EDSA by emailGet an email when EDSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EDSA, unsubscribe in one click. Privacy
📣 What EDSA Says Is Next
fourth quarter 2027 · “The Company anticipates that topline data will be available fourth quarter 2027.”
Company press release, Oct 15, 2026 · SEC filing
coming weeks · “"Our third quarter marked an important operational inflection point for Edesa, with the completion of preparations for our Phase 2 vitiligo study keeping us on track for initial enrollment in the coming weeks," said Par Nijhawan, MD, Chief Executive Officer of Edesa.”
Company press release, Aug 13, 2026 · SEC filing
coming weeks · “Subsequent to quarter-end, the company began activating its first investigational sites and expects recruitment to begin in the coming weeks in Canada, with additional jurisdictions to follow, subject to regulatory approval and administrative filings.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Regulatory The European Commission granted orphan designation to paridiprubart for treating Acute Respiratory Distress Syndrome, following a positive opinion from the EMA's Committee for Orphan Medicinal Products. The designation is entered in the Community Register as EU/3/26/3320. Form 8-K · SEC filing
Nov 9, 2026 ·
Deal Entered a license deal giving Kyorin exclusive Japan rights to paridiprubart for ARDS, with a $12 million upfront payment, up to $55 million in development and regulatory milestones, up to ¥12.0 billion in sales milestones, and low double-digit tiered royalties. Also terminated the ATM sales agreement with H.C. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Leadership Edesa raised the base salaries of CEO Pardeep Nijhawan from $357,696 to $657,423, President Michael Brooks from $335,340 to $591,681, and CFO Peter Weiler from $300,000 to $525,938, retroactive to July 1, 2026. Salaries had last been adjusted in 2023. Form 8-K · SEC filing
Aug 20, 2026 ·
Financing Edesa Biotech is offering 3,870,500 common shares at $5.50 per share, plus pre-funded warrants for up to 675,000 shares and accompanying common share warrants at $7.50 exercisable until the earlier of 18 months or 30 days after Phase 2 vitiligo topline data for EB06. Form 424B5 · SEC filing
Aug 20, 2026 ·
Financing Edesa Biotech entered an underwritten offering with Guggenheim Securities of 3,870,500 common shares at $5.50 each, plus pre-funded warrants and common share warrants, with a 681,825-share overallotment option. Expected net proceeds are about $23.1 million, closing on or about August 21, 2026. Form 8-K · SEC filing · Press release
Aug 19, 2026 ·
Financing Edesa Biotech filed a preliminary prospectus for a proposed offering of common shares, pre-funded warrants, and common share warrants, with the offering amount and price left blank. Warrants are exercisable until the earlier of 18 months or 30 days after Phase 2 vitiligo topline data for EB06. Form 424B5 · SEC filing
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 2 · Recruiting · A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo Registry primary completion date, not a results date
Jul 2028 · Phase 2 · Recruiting · JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart Registry primary completion date, not a results date
Jul 2028 · Phase 2 · Recruiting · JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Registry primary completion date, not a results date
Jul 2028 · Phase 2 · Recruiting · JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab Registry primary completion date, not a results date
Jul 2028 · Phase 2 · Recruiting · JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
EDSA holds $10.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations,
an estimated runway of 12.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:47 · Elevated
Cash runway 12 months +18
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Jul 2025) +10
Share count +37% in a year +14
Raised after last reported balance sheet (Aug 2026) -10
Share count 9,641,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full EDSA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EDSA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.